Asset Publisher

mp-613

print Print

Nutrient/Nutritional Panel Testing

Policy Number: MP-613

Latest Review Date: December 2024

Category:  Laboratory                                                            

POLICY:

Nutrient/nutritional panel testing is considered investigational for all indications including but not limited to testing for nutritional deficiencies in individuals with mood disorders, fibromyalgia, or unexplained fatigue and healthy individuals.

DESCRIPTION OF PROCEDURE OR SERVICE:

Multimarker nutritional panel testing is proposed for patients with certain chronic conditions (e.g., mood disorders, fibromyalgia, and unexplained fatigue) as well as for healthy individuals seeking to optimize health and/or fitness.

Nutritional panel testing aims to identify nutritional deficiencies that will lead to personalized nutritional supplement recommendations. Testing is proposed both for healthy individuals to optimize health and for patients with chronic conditions (e.g., mood disorders, fibromyalgia, unexplained fatigue) to specify supplements that will ameliorate symptoms.

Genova Diagnostics offers nutritional/nutrient panel testing. Among tests offered by this company is the NutrEval® FMV test, which involves analysis of urine and blood samples and provides information on more than 100 markers including organic acids, amino acids, fatty acids, markers of oxidative stress (direct measurement of glutathione and CoQ10, and markers of oxidative injury and DNA damage) and nutrient elements (see Table 1).

Genova Diagnostics produces a report that includes test results categorized as minimal, moderate, or high need for support, along with recommendations for supplements and dosages for items categorized as high need. NutrEval® FMV patient reports can recommend supplementation for any of the nutrients listed in Table 1 if they are found to be areas of high need.

NutrEval Plasma, also by Genova Diagnostics, is a similar test. The only difference between NutrEval FMV and NutrEval Plasma is that the former uses urine (first morning void) whereas the latter uses plasma (fasting sample) to measure amino acids.

SpectraCell Laboratories offers a micronutrient test that measures functional deficiencies at the cellular level. The test assesses how well the body uses 31 vitamins, minerals, amino and fatty acids, antioxidants, and metabolites (see Table 1). SpectraCell categorizes test results into adequate, borderline, and deficient, and offers supplementation suggestions based on each patient’s deficiencies.

 

Table 1: Components of the NutrEval FMV Test

Category

NutrEval

SpectraCell Nutrient Testing

Vitamins and antioxidants

Vitamin A, vitamin C, vitamin E, alpha-lipoic acid,coenzyme Q10, glutathione, plant-based antioxidants, Bvitamins (Thiamin B1, riboflavin B2, niacin B3, pyridoxine B6, biotin B7, folic acid B9, cobalamin B12)

Vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, biotin, folate, pantothenate, vitamin C, vitamin D, vitamin K, alpha-lipoic acid, coenzyme Q10, cysteine,glutathione, selenium, vitamin E

Minerals

Magnesium, manganese, molybdenum, zinc

Calcium, magnesium, manganese, zinc, copper

Fatty Acids

Omega-3-oils

 

Digestive Support

Probiotics, pancreatic enzymes

 

Other Vitamins

Vitamin D

 

Amino Acids

Arginine, asparagine, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lycine, methionine, phenylalanine, serine, taurine, threonine, tryptophan, tyrosine, valine

Asparagine, glutamine, serine

Metabolites

 

Choline, inositol, carnitine

KEY POINTS:

The most recent literature update was performed through October 16, 2024.

Summary of Evidence:

For individuals who have mood disorders, fibromyalgia, or unexplained fatigue, or healthy individuals who seek to optimize health and fitness who receive nutritional panel testing, the evidence includes several systematic reviews and RCTs on the association between a single condition and a single nutrient and on the treatment of specific conditions with nutritional supplements. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Systematic reviews have found statistically significant associations between depression or fibromyalgia and levels of several nutrients; however, there is little evidence that nutrient supplementation for patients with depression improves health outcomes. An RCT has also found statistically significant associations between fatigue and levels of vitamin D. However, there is no direct evidence on the health benefits of nutritional panel testing for any condition, including testing healthy individuals, and no evidence that nutritional panel testing is superior to testing for individual nutrients for any condition. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements

No guidelines or statements were identified.

U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force (USPSTF) has not addressed nutritional panel testing. The USPSTF has made several recommendations addressing screening for individual nutrients.

The USPSTF concluded that there is insufficient evidence to recommend for or against screening for iron deficiency anemia in asymptomatic children, adolescents and pregnant women, as well as vitamin D deficiency in asymptomatic, nonpregnant adults.

KEY WORDS:

Genova Diagnostics, NutrEval® FMV, Nutrient panel testing, nutritional panel testing, ONE FMV™, Optimal Nutritional Evaluation, Metabolomix+, NutrEval Plasma

APPROVED BY GOVERNING BODIES:

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Nutrient/nutritional panel testing using urine and/or blood samples is offered (e.g., NutrEval FMV® and

NutrEval Plasma® by Genova Diagnostics; micronutrient testing by SpectraCell) under the auspices of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

BENEFIT APPLICATION:

Coverage is subject to member’s specific benefits. Group-specific policy will supersede this policy when applicable.

ITS: Home Policy provisions apply.

FEP:  Special benefit consideration may apply.  Refer to member’s benefit plan. 

CURRENT CODING:

CPT Codes:

There are no specific codes for these panels of tests.

82128

Amino acids; multiple, qualitative, each specimen

82136

Amino acids, 2 to 5 amino acids, quantitative, each specimen

82746

Folic acid; serum

83735

Magnesium

83785

Manganese

84590

Vitamin A

84630

 

Zinc

84999

Unlisted chemistry code

REFERENCES:

  1. Anglin RE, Samaan Z, Walter SD, et al. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry. Feb 2013; 202:100-107.
  2. Cheungpasitporn W, Thongprayoon C, Mao MA, et al. Hypomagnesaemia linked to depression: a systematic review and meta-analysis. Intern Med J. Apr 2015; 45(4):436-440.
  3. Daniel D, Pirotta MV. Fibromyalgia--should we be testing and treating for vitamin D deficiency? Aust Fam Physician. Sep 2011; 40(9):712-716.
  4. Genova Diagnostics. NutrEval FMV. 2015; www.gdx.net/product/nutreval-fmv-nutritional-test-blood-urine. Accessed October 20, 2023.
  5. Genova Diagnostics. NutrEval Plasma; www.gdx.net/product/nutreval-nutritional-test-plasma. Accessed October 21, 2023.
  6. Gowda U, Mutowo MP, Smith BJ, et al. Vitamin D supplementation to reduce depression in adults: meta-analysis of randomized controlled trials. Nutrition. Mar 2015; 31(3):421-429.
  7. Hsiao MY, Hung CY, Chang KV, et al. Is serum hypovitaminosis D associated with chronic widespread pain including fibromyalgia? A meta-analysis of observational studies. Pain Physician. Sep-Oct 2015; 18(5):E877-887.
  8. IOM (Institute of Medicine). 2011. Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press.
  9. Nowak A, Boesch L, Andres E, et al. Effect of vitamin D3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial. Medicine (Baltimore). Dec 2016; 95(52):e5353.
  10. Petridou ET, Kousoulis AA, Michelakos T, et al. Folate and B12 serum levels in association with depression in the aged: a systematic review and meta-analysis. Aging Ment Health. Jun 8 2015:1-9.
  11. SpectraCell Laboratories Micronutrient Test Panel. www.spectracell.com/micronutrient-test-panel.  Accessed October 21, 2023.
  12. Swardfager W, Herrmann N, Mazereeuw G, et al. Zinc in depression: a meta-analysis. Biol Psychiatry. Dec 15 2013; 74(12):872-878.
  13. Taylor MJ, Carney S, Geddes J, et al. Folate for depressive disorders. Cochrane Database Syst Rev. 2003(2):CD003390.
  14. U.S. Preventive Services Task Force (USPSTF). Iron Deficiency Anemia in Pregnant Women: Screening and Supplementation, 2015. www.uspreventiveservicestaskforce.org/uspstf/recommendation/iron-deficiency-anemia-in-pregnant-women-screening-and-supplementation. Accessed October 19, 2023.
  15. U.S. Preventive Services Task Force (USPSTF). Vitamin D Deficiency: Screening. 2015; www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/vitamin-d-deficiency-screening. Accessed October 20, 2023.
  16.  U.S. Preventive Services Task Force (USPSTF). Vitamin D Deficiency: Screening. 2021; www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-d-deficiency-screening.

POLICY HISTORY:

Medical Policy Panel, August 2015

Medical Policy Group, September 2015 (3):  Newly adopted policy.

Medical Policy Administration Committee, October 2015

Available for comment September 29 through November 12, 2015

Medical Policy Panel, December 2017

Medical Policy Group, January 2018 (3): 2017 Updates to Description, Key Points, Approved by Governing Bodies & References; no change to policy statement.

Medical Policy Panel, December 2018

Medical Policy Group, December 2018 (6): Updates to Key Points and U.S. Preventive Services Task Force Recommendations.

Medical Policy Panel, December 2019

Medical Policy Group, December 2019 (6): Updates to Key Points and References.

Medical Policy Group, October 2020 (6): Added Key Word: Metabolomix+

Medical Policy Panel, December 2020

Medical Policy Group, December 2020 (6): Updates to Description, Key Points, U.S. Preventive Services and References.

Medical Policy Panel, December 2021

Medical Policy Group, December 2021 (6) Updates to Key Points, USPSTF and References.

Medical Policy Panel, December 2022

Medical Policy Group, December 2022 (6): Updates to Description, Key Points, Governing Bodies, USPSTF, Key Words and References.

Medical Policy Panel, December 2023

Medical Policy Group, December 2023 (5): Updates to Key Points, Benefit Application, and References.   No change to policy statement.

Medical Policy Panel, December 2024

Medical Policy Group, December 2024 (5): Minor update to Key Points and References. No change to Policy Statement.  

                                                                                                                                   

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

 

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield’s administration of plan contracts.

The plan does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. The plan administers benefits based on the member’s contract and corporate medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

As a general rule, benefits are payable under health plans only in cases of medical necessity and only if services or supplies are not investigational, provided the customer group contracts have such coverage.

The following Association Technology Evaluation Criteria must be met for a service/supply to be considered for coverage:

1. The technology must have final approval from the appropriate government regulatory bodies;

2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes;

3. The technology must improve the net health outcome;

4. The technology must be as beneficial as any established alternatives;

5. The improvement must be attainable outside the investigational setting.

 

Medical Necessity means that health care services (e.g., procedures, treatments, supplies, devices, equipment, facilities or drugs) that a physician, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury or disease or its symptoms, and that are:

1. In accordance with generally accepted standards of medical practice; and

2. Clinically appropriate in terms of type, frequency, extent, site and duration and considered effective for the patient’s illness, injury or disease; and

3. Not primarily for the convenience of the patient, physician or other health care provider; and

4. Not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient’s illness, injury or disease.